De-implementing low-value care in cancer care delivery: a systematic review

被引:17
作者
Alishahi Tabriz, Amir [1 ,2 ]
Turner, Kea [1 ,2 ]
Clary, Alecia [3 ]
Hong, Young-Rock [4 ,5 ]
Nguyen, Oliver T. [6 ,7 ]
Wei, Grace [2 ]
Carlson, Rebecca B. [8 ]
Birken, Sarah A. [9 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, 4115 Fowler Ave, Tampa, FL 33617 USA
[2] Univ S Florida, Dept Oncol Sci, Morsani Coll Med, 560 Channelside Dr, Tampa, FL 33602 USA
[3] Reagan Udall Fdn FDA, 1900 L St,Suite 835, Washington, DC 20036 USA
[4] UF Hlth Canc Ctr, Gainesville, FL USA
[5] Univ Florida, Dept Hlth Serv Res Management & Policy, Coll Publ Hlth & Hlth Profess, HPNP Bldg,Room 3111, Gainesville, FL 32610 USA
[6] Univ Florida, Dept Community Hlth & Family Med, POB 100211, Gainesville, FL 32610 USA
[7] Univ Alabama Birmingham, Dept Hlth Serv Adm, Birmingham, AL USA
[8] Univ N Carolina, Hlth Sci Lib, 335 S Columbia St, Chapel Hill, NC 27599 USA
[9] Wake Forest Sch Med, Dept Implementat Sci, 525 Vine Room 5219,Med Ctr Blvd, Winston Salem, NC 27157 USA
关键词
De-implementation; De-adoption; Low-value care; Low-value service; Cancer; Cancer care delivery; Oncology; Overuse; Choosing wisely; BREAST-CANCER; OVERUSE; SERVICES; OLDER; MEN; MANAGEMENT; MORTALITY; BENEFITS; SUPPORT; IMPROVE;
D O I
10.1186/s13012-022-01197-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Accumulating evidence suggests that interventions to de-implement low-value services are urgently needed. While medical societies and educational campaigns such as Choosing Wisely have developed several guidelines and recommendations pertaining to low-value care, little is known about interventions that exist to de-implement low-value care in oncology settings. We conducted this review to summarize the literature on interventions to de-implement low-value care in oncology settings. Methods We systematically reviewed the published literature in PubMed, Embase, CINAHL Plus, and Scopus from 1 January 1990 to 4 March 2021. We screened the retrieved abstracts for eligibility against inclusion criteria and conducted a full-text review of all eligible studies on de-implementation interventions in cancer care delivery. We used the framework analysis approach to summarize included studies' key characteristics including design, type of cancer, outcome(s), objective(s), de-implementation interventions description, and determinants of the de-implementation interventions. To extract the data, pairs of authors placed text from included articles into the appropriate cells within our framework. We analyzed extracted data from each cell to describe the studies and findings of de-implementation interventions aiming to reduce low-value cancer care. Results Out of 2794 studies, 12 met our inclusion criteria. The studies covered several cancer types, including prostate cancer (n = 5), gastrointestinal cancer (n = 3), lung cancer (n = 2), breast cancer (n = 2), and hematologic cancers (n = 1). Most of the interventions (n = 10) were multifaceted. Auditing and providing feedback, having a clinical champion, educating clinicians through developing and disseminating new guidelines, and developing a decision support tool are the common components of the de-implementation interventions. Six of the de-implementation interventions were effective in reducing low-value care, five studies reported mixed results, and one study showed no difference across intervention arms. Eleven studies aimed to de-implement low-value care by changing providers' behavior, and 1 de-implementation intervention focused on changing the patients' behavior. Three studies had little risk of bias, five had moderate, and four had a high risk of bias. Conclusions This review demonstrated a paucity of evidence in many areas of the de-implementation of low-value care including lack of studies in active de-implementation (i.e., healthcare organizations initiating de-implementation interventions purposefully aimed at reducing low-value care).
引用
收藏
页数:16
相关论文
共 72 条
  • [1] Mortality Results from a Randomized Prostate-Cancer Screening Trial
    Andriole, Gerald L.
    Grubb, Robert L., III
    Buys, Saundra S.
    Chia, David
    Church, Timothy R.
    Fouad, Mona N.
    Gelmann, Edward P.
    Kvale, Paul A.
    Reding, Douglas J.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    Crawford, E. David
    O'Brien, Barbara
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hayes, Richard B.
    Kramer, Barnett S.
    Izmirlian, Grant
    Miller, Anthony B.
    Pinsky, Paul F.
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) : 1310 - 1319
  • [2] [Anonymous], Study Quality Assessment Tools
  • [3] Determinants for the use and de-implementation of low-value care in health care: a scoping review
    Augustsson, Hanna
    Ingvarsson, Sara
    Nilsen, Per
    von Thiele Schwarz, Ulrica
    Muli, Irene
    Dervish, Jessica
    Hasson, Henna
    [J]. IMPLEMENTATION SCIENCE COMMUNICATIONS, 2021, 2 (01):
  • [4] Scope and Characteristics of Choosing Wisely in Cancer Care Recommendations by Professional Societies
    Baskin, Alison S.
    Wang, Ton
    Berlin, Nicholas L.
    Skolarus, Ted A.
    Dossett, Lesly A.
    [J]. JAMA ONCOLOGY, 2020, 6 (09) : 1463 - 1465
  • [5] Overuse of Health Care Services in the Management of Cancer A Systematic Review
    Baxi, Shrujal S.
    Kale, Minal
    Keyhani, Salomeh
    Roman, Benjamin R.
    Yang, Annie
    Derosa, Antonio P.
    Korenstein, Deborah
    [J]. MEDICAL CARE, 2017, 55 (07) : 723 - 733
  • [6] Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature
    Bierbaum, Mia
    Rapport, Frances
    Arnolda, Gaston
    Easpaig, Brona Nic Giolla
    Lamprell, Klay
    Hutchinson, Karen
    Delaney, Geoff P.
    Liauw, Winston
    Kefford, Richard
    Olver, Ian
    Braithwaite, Jeffrey
    [J]. IMPLEMENTATION SCIENCE, 2020, 15 (01)
  • [7] Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?
    Boughey, Judy C.
    Haffty, Bruce G.
    Habermann, Elizabeth B.
    Hoskin, Tanya L.
    Goetz, Matthew P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (03) : 614 - 617
  • [8] Implementation of a clinical decision support system improves compliance with restrictive transfusion policies in hematology patients
    Butler, Caroline E.
    Noel, Simon
    Hibbs, Stephen P.
    Miles, David
    Staves, Julie
    Mohaghegh, Payam
    Altmann, Paul
    Curnow, Elinor
    Murphy, Michael F.
    [J]. TRANSFUSION, 2015, 55 (08) : 1964 - 1971
  • [9] Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Cardoso, F.
    Harbeck, N.
    Fallowfield, L.
    Kyriakides, S.
    Senkus, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 11 - 19
  • [10] Evidence That Consumers Are Skeptical About Evidence-Based Health Care
    Carman, Kristin L.
    Maurer, Maureen
    Yegian, Jill Mathews
    Dardess, Pamela
    McGee, Jeanne
    Evers, Mark
    Marlo, Karen O.
    [J]. HEALTH AFFAIRS, 2010, 29 (07) : 1400 - 1406